Regenera Pharma

Regenerative Therapy for Neuropathies

Health Tech & Life Sciences
Non Active, Nov 2020 ceased to operate

Company Overview

Snapshot

Founded in June 2008, Regenera Pharma operates with 1–10 employees. The company has raised $24.02 million across four funding rounds. In August 2018, Regenera Pharma enrolled its first patient in a US Phase 3 study for RPh201 in NAION and advanced a Phase 2 study in Alzheimer's Disease in Canada.

Business overview

Regenera Pharma is a clinical-stage pharmaceutical company focused on developing innovative drugs for the treatment of optic nerve neuropathies, with a particular emphasis on ischemic optic neuropathy. The company's core product, RPh201, is being evaluated in clinical trials for conditions such as non-arteritic anterior ischemic optic neuropathy (NAION) and Alzheimer's disease. Regenera Pharma operates within the Health Tech & Life Sciences sector, specifically targeting the biopharmaceutical, neurology, and regenerative medicine markets.

Strategic signal

In November 2020, a trustee was appointed for Regenera Pharma, indicating a significant operational shift for the company. This development signals to investors and innovation teams that the company ceased operations around this time, marking a critical transition in its corporate trajectory.

Company Intelligence Q&A

What is Regenera Pharma's primary focus?
Regenera Pharma is a clinical-stage pharmaceutical company developing innovative drugs for the treatment of optic nerve neuropathies, with a current focus on ischemic optic neuropathy.
When did Regenera Pharma enroll its first patient in the US Phase 3 study for RPh201?
In August 2018, Regenera Pharma enrolled its first patient in a US Phase 3 study of RPh201 for NAION and also advanced a Phase 2 study in Alzheimer's Disease in Canada.
What was a significant corporate event for Regenera Pharma in November 2020?
In November 2020, a trustee was appointed for Regenera Pharma, indicating that the company ceased to operate.
Has Regenera Pharma published any study data for RPh201?
In May 2019, Regenera Pharma announced the publication of RPh201 Phase 2a study data for the treatment of NAION in the Journal of Neuro-Ophthalmology.
Which investor participated in a funding round for Regenera Pharma in January 2018?
In January 2018, aMoon Fund participated in a funding round for Regenera Pharma.

External links